Talk:Dz13

message: Change: under ”Mechanism of action”; include:  
It has been reported off-target effects of Dz13, not related to the inactivation of c-Jun      
Change: under “References”; include:
Rivory, L. et al (2006) The DNAzymes Rs6, Dz13, and DzF have potent biologic effects independent of catalytic activity. Oligonucleotides 16, 297–312.
Goodchild, A. et al (2007) Cytotoxic G-rich oligode-oxynucleotides: putative protein targets and required sequence motif. Nucleic Acids Res. 35, 4562–4572.
Gozar, M.M. et al (2008) Dz13, a DNAzyme Targeting c-jun, Induces Off-Target Cytotoxicity in Endothelial Cells with Features of Nonapoptotic Programmed Cell Death. Oligonucleotides 18(3), 257-268.
Change: under “Investigations”, before the sentence “A series of investigations”; include:
Six of Khachigian's research articles have been retracted and one corrected due to unresolved concerns over missing or manipulated data. http://retractionwatch.com/2013/08/12/aussie-university-halts-trials-of-skin-cancer-drug-whose-developer-has-four-retractions/ https://retractionwatch.com/2013/11/04/jbc-issues-correction-for-paper-by-khachigian-who-has-had-four-others-retracted/ 
http://retractionwatch.com/2019/01/14/an-australian-university-cleared-a-cancer-researcher-of-misconduct-hes-now-retracted-six-papers/
Change: under “Investigations”, end of paragraph; include:
“This conclusion has been challenged”.https://www.abc.net.au/news/2019-10-17/unsw-skin-cancer-levon-khachigian-allegations-and-retractions/11585768
Reason for change: important to include more information from another point of view. Moroks (talk) 13:28, 5 December 2019 (UTC)
replies: text: Not done for now: please establish a consensus for this alteration before using the  template. — Martin (MSGJ · talk) 22:33, 5 December 2019 (UTC)
thread_title:  Protected edit request on 5 December 2019 

message: Change: Under the headline “Mechanism of action”; include as the third paragraph:
Oligonucleotides such as Dz13 may be used with carriers such as cationic polymers for improved cellular delivery and efficacy. Dz13 in such polymers inhibits tumor cell proliferation and migration by suppressing levels of c-Jun and MMPs, reduces H1N1 and H7N2 viral replication and increases survival of mice infected with influenza A and suppresses c-Jun and solid tumor growth in biomimetic nanoballs. Dz13 has also been used in dermal drug delivery systems for enhanced skin penetration of DNAzyme.
Under “References”; include:
Kynova, R. et al (2014) Enhancing nucleic acid delivery, insights from the cationic phospholipid carriers. Current Pharmaceutical Biotechnology 15(9), 806-13.
Yang. J. et al (2019) Inhibition of proliferation and migration of tumor cells through phenylboronic acid-functionalized polyamidoamine-mediated delivery of a therapeutic DNAzyme Dz13. International Journal of Nanomedicine 14, 6371–6385.
Zhang, Z. et al (2017) DNAzymes Dz13 target the c-jun possess antiviral activity against influenza A viruses. Microbial Pathogenesis 103, 155-161.
Kim, M.-G. et al (2015) Biomimetic DNA nanoballs for oligonucleotide delivery. Biomaterials 62, 155-163.
Marquardt, K. et al (2015) Development of a protective dermal drug delivery system for therapeutic DNAzymes. International Journal of Pharmaceutics 479, 150-158.
Reason for change: 
Provides critical information on Dz13 from different laboratories.
Moroks suggested on 5 December 2019 to “Change: under “Investigations”, before the sentence “A series of investigations”; include: Six of Khachigian's research articles have been retracted and one corrected due to unresolved concerns over missing or manipulated data. [4] [5] [6]”. This sentence should not be included since it is neither relevant nor factual as explained below.
Reasons for not inserting Moroks’ proposed sentence:
(a) Only one (1) of the 6 retracted articles relates to Dz13.http://retractiondatabase.org/RetractionSearch.aspx#?auth%3dKhachigian%252c%2bLevon%2bM This is the “2010 paper” already noted in the existing first sentence “In 2013, trials of Dz13 …”. It is mischievous to refer to the 5 other papers on this page as these do not relate to Dz13;  
(b) None of the publisher retraction notices for any of these 6 research articles refer to manipulated data;http://retractiondatabase.org/RetractionSearch.aspx#?auth%3dKhachigian%252c%2bLevon%2bM  
(c) Although data manipulation was initially alleged, the independent expert panels investigating this article found genuine error or honest oversight, not deliberate or intentional conduct.https://retractionwatch.com/2015/12/15/cancer-researcher-cleared-of-misconduct-inquiry-finds-genuine-error-or-honest-oversight/ https://www.theaustralian.com.au/higher-education/unsw-clears-levon-khachigian-of-all-allegations-of-research-misconduct/news-story/f707b2c14b5cc251a4db5fcbe5778002
----  — Preceding unsigned comment added by HansonPeabody (talk • contribs) 21:17, 10 December 2019 (UTC)
thread_title:  Protected edit request on 10 December 2019 

message: Change: Under the headline “Mechanism of action”; include as the third paragraph:
Oligonucleotides such as Dz13 may be used with carriers such as cationic polymers for improved cellular delivery and efficacy. Dz13 in such polymers inhibits tumor cell proliferation and migration by suppressing levels of c-Jun and MMPs, reduces H1N1 and H7N2 viral replication and increases survival of mice infected with influenza A and suppresses c-Jun and solid tumor growth in biomimetic nanoballs. Dz13 has also been used in dermal drug delivery systems for enhanced skin penetration of DNAzyme.
Under “References”; include:
Kynova, R. et al (2014) Enhancing nucleic acid delivery, insights from the cationic phospholipid carriers. Current Pharmaceutical Biotechnology 15(9), 806-13.
Yang. J. et al (2019) Inhibition of proliferation and migration of tumor cells through phenylboronic acid-functionalized polyamidoamine-mediated delivery of a therapeutic DNAzyme Dz13. International Journal of Nanomedicine 14, 6371–6385.
Zhang, Z. et al (2017) DNAzymes Dz13 target the c-jun possess antiviral activity against influenza A viruses. Microbial Pathogenesis 103, 155-161.
Kim, M.-G. et al (2015) Biomimetic DNA nanoballs for oligonucleotide delivery. Biomaterials 62, 155-163.
Marquardt, K. et al (2015) Development of a protective dermal drug delivery system for therapeutic DNAzymes. International Journal of Pharmaceutics 479, 150-158.
Reason for change: 
Provides critical information on Dz13 from different laboratories.
Moroks suggested on 5 December 2019 to “Change: under “Investigations”, before the sentence “A series of investigations”; include: Six of Khachigian's research articles have been retracted and one corrected due to unresolved concerns over missing or manipulated data. [4] [5] [6]”. This sentence should not be included since it is neither relevant nor factual as explained below.
Reasons for not inserting Moroks’ proposed sentence:
(a) Only one (1) of the 6 retracted articles relates to Dz13.http://retractiondatabase.org/RetractionSearch.aspx#?auth%3dKhachigian%252c%2bLevon%2bM This is the “2010 paper” already noted in the existing first sentence “In 2013, trials of Dz13 …”. It is mischievous to refer to the 5 other papers on this page as these do not relate to Dz13;  
(b) None of the publisher retraction notices for any of these 6 research articles refer to manipulated data;http://retractiondatabase.org/RetractionSearch.aspx#?auth%3dKhachigian%252c%2bLevon%2bM  
(c) Although data manipulation was initially alleged, the independent expert panels investigating this article found genuine error or honest oversight, not deliberate or intentional conduct.https://retractionwatch.com/2015/12/15/cancer-researcher-cleared-of-misconduct-inquiry-finds-genuine-error-or-honest-oversight/ https://www.theaustralian.com.au/higher-education/unsw-clears-levon-khachigian-of-all-allegations-of-research-misconduct/news-story/f707b2c14b5cc251a4db5fcbe5778002
HansonPeabody (talk) 21:33, 10 December 2019 (UTC)
thread_title:  Protected edit request on 10 December 2019 (signed)